Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial

Annals of Oncology · Elsevier

Аннотация

Publication date: Available online 23 October 2026 Source: Annals of Oncology Author(s): D.J. Slamon, G.N. Hortobagyi, D. Stroyakovskiy, D.A. Yardley, C.-S. Huang, J. Crown, A. Bardia, S. Chia, S.-A. Im, M. Martin, S. Loi, B. Xu, S.A. Hurvitz, C.H. Barrios, A. Cuesta Fernández, M. Untch, F. Visco, A.L. Perez, M. Miller, S. Majumdar

Читать у издателя →

Похожие статьи